---
schema_version: "secwatch.filing_event.v1"
accession: "0001453687-25-000119"
form_type: "8-K"
ticker: "RNAC"
cik: "0001453687"
company_name: "Cartesian Therapeutics, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:35:47.076009+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cartesian Q3 net loss $35.9M; cash $145.1M; AURORA trial on track

## Summary
- Net loss of $35.9M ($1.38/share) vs $24.2M ($1.13/share) in Q3 2024.
- Cash, equivalents and restricted cash $145.1M, expected to fund ops into mid-2027.
- Phase 3 AURORA enrollment on track; ~100 participants, primary endpoint at Month 4.
- Preliminary Phase 2 SLE data and pediatric basket trial initiation expected by end of 2025.
- R&D expense $13.8M (+21% YoY) due to AURORA trial and headcount growth.

## SEC filing metadata
- accession: 0001453687-25-000119
- form_type: 8-K
- ticker: RNAC
- cik: 0001453687
- company_name: Cartesian Therapeutics, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000119/0001453687-25-000119-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000119/rnac-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001453687-25-000119
- JSON: https://secwatch.observer/filing/0001453687-25-000119.json
- Plain text: https://secwatch.observer/filing/0001453687-25-000119.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.